A detailed history of Pfg Advisors transactions in Eli Lilly & CO stock. As of the latest transaction made, Pfg Advisors holds 3,417 shares of LLY stock, worth $2.56 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
3,417
Previous 3,364 1.58%
Holding current value
$2.56 Million
Previous $3.05 Million 0.59%
% of portfolio
0.2%
Previous 0.21%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$772.14 - $960.02 $40,923 - $50,881
53 Added 1.58%
3,417 $3.03 Million
Q2 2024

Aug 07, 2024

BUY
$724.87 - $909.04 $287,048 - $359,979
396 Added 13.34%
3,364 $3.05 Million
Q1 2024

May 06, 2024

BUY
$592.2 - $792.28 $564,958 - $755,835
954 Added 47.37%
2,968 $2.31 Million
Q4 2023

Jan 19, 2024

SELL
$525.19 - $619.13 $2,100 - $2,476
-4 Reduced 0.2%
2,014 $1.17 Million
Q3 2023

Oct 13, 2023

SELL
$434.7 - $599.3 $1.16 Million - $1.6 Million
-2,678 Reduced 57.03%
2,018 $1.08 Million
Q2 2023

Jul 20, 2023

BUY
$350.74 - $468.98 $539,087 - $720,822
1,537 Added 48.65%
4,696 $2.2 Million
Q1 2023

Apr 20, 2023

BUY
$310.63 - $364.82 $604,485 - $709,939
1,946 Added 160.43%
3,159 $1.08 Million
Q4 2022

Jan 27, 2023

BUY
$321.55 - $374.67 $17,042 - $19,857
53 Added 4.57%
1,213 $443,000
Q3 2022

Oct 13, 2022

SELL
$296.48 - $337.87 $18,974 - $21,623
-64 Reduced 5.23%
1,160 $375,000
Q2 2022

Jul 13, 2022

BUY
$278.73 - $327.27 $36,792 - $43,199
132 Added 12.09%
1,224 $397,000
Q1 2022

Apr 19, 2022

SELL
$234.69 - $291.66 $2,346 - $2,916
-10 Reduced 0.91%
1,092 $313,000
Q3 2021

Nov 05, 2021

SELL
$221.6 - $272.71 $44,320 - $54,541
-200 Reduced 15.36%
1,102 $255,000
Q2 2021

Jul 28, 2021

SELL
$180.55 - $233.54 $3,069 - $3,970
-17 Reduced 1.29%
1,302 $299,000
Q1 2021

Apr 27, 2021

BUY
$164.32 - $212.72 $216,738 - $280,577
1,319 New
1,319 $246,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $713B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Pfg Advisors Portfolio

Follow Pfg Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfg Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Pfg Advisors with notifications on news.